Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03773133 · ClinicalTrials.gov registry record · Phase 1
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
A Phase 1 study, sponsored by Ipsen.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT03773133 is a Phase 1 study that was terminated before completion, run by Ipsen. The registered enrollment target is 9 participants.
The verdict
NCT03773133, a Phase 1 study, was terminated before completion, sponsored by Ipsen.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v. administrations in pre-treated subjects with locally advanced or metastatic cancers expressing sstr2 as identified by Satoreotide trizoxetan Positron Emission Tomography (PET/CT) scans. This phase will encompass both radioactivity escalation and peptide mass dose evaluation. Phase II will assess the efficacy of Satoreotide tetraxetan in subjects in selected indications, in a basket design.
Interventions
- DRUG Satoreotide tetraxetan
- DRUG Satoreotide trizoxetan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2019-05-14 |
| Est. Completion | 2019-10-10 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03773133
The ClinicalTrials.gov registry entry for NCT03773133 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ipsen, which has 85 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Satoreotide tetraxetan is the first listed.
NCT03773133 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03773133 about?
NCT03773133 is a clinical study titled "Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)". This study consists of two phases. The phase I study is designed to investigate the safety and tolerability of Satoreotide tetraxetan following fractionated i.v. administrations in pre-treated subjects with locally advanced or metastatic cancers expressing sstr2 as identified by Satoreotide trizoxet...
What is the current status of trial NCT03773133?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2019-05-14. Estimated completion is 2019-10-10.
What interventions are being tested in trial NCT03773133?
The interventions under investigation include: Satoreotide tetraxetan (DRUG), Satoreotide trizoxetan (DRUG).
Who is sponsoring clinical trial NCT03773133?
This trial is sponsored by Ipsen, which has 85 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.